SomaLogic

02/18/2025

Discover how proteomics drives breakthroughs!

Join us at US HUPO 2025 for an exclusive Breakfast Symposium:
📅 February 24 | ⏰ 7:15–8:15 am | 📍 Commonwealth C

Topic: Unlocking Insights: Leveraging Large-Scale Proteogenomic Data to Identify Proteomic Drivers of Human Diseases – a Comprehensive Catalog of Proteome-Phenome-Wide Associations
Speaker: Satoshi Yoshiji, MD, PhD

🎟️ Bonus: The first 25 attendees get a drink ticket for evening workshops!

Why attend?
- Learn how proteogenomic data reshapes disease research
- Identify new therapeutic targets for inflammatory and metabolic diseases
- Network with leaders in precision proteomics

🔗 Visit Booth 13 to see the SomaScan™ Platform in action – measuring 11,000 proteins from a single sample to fuel your research.

👉 Register now: https://somalogic.com/us-hupo-2025/?utm_source=LI&utm_medium=SM

02/06/2025

Take biomarker discovery, target validation and clinical trials to the next level with the most precise proteomic tool available today. Hear Joe Coresh, MD, PhD, compare the SomaScan™ Assay with high-plex antibody assays.

💻 Watch the full video here: https://somalogic.com/webinar/evaluation-of-precision-and-correlation-for-the-latest-proteomic-platforms/?utm_source=FB&utm_medium=SM

01/06/2025

📢 We're excited to share the latest publication in Nature Medicine: "Proteomic changes upon treatment with semaglutide in individuals with obesity."

Researchers at Novo Nordisk used the SomaScan™ platform to study the effects of semaglutide on blood proteins, providing new insights into the drug’s impact on metabolic health beyond weight loss and glucose regulation.

Key highlights:
👉 Standard BioTools’ SomaScan™ Assay was used to profile approximately 6,400 unique human proteins in nearly 2,000 participants
👉 The data provided insights into disease mechanisms and drug repurposing opportunities and highlighted the value of measuring changes in blood proteins in response to weight loss drugs

🎯 Read the full article here! https://www.nature.com/articles/s41591-024-03355-2

12/26/2024

👇 Read our latest case study and explore how unbiased proteomics can drive novel diagnostic and therapeutic developments! https://somalogic.com/eyeing-thousands-of-proteins-for-biomarker-discovery/?utm_source=LI&utm_medium=SM

By leveraging the unmatched precision of the SomaScan™ high-plex proteomic platform, researchers are uncovering new strategies for diagnosing and treating diseases that affect the eyes as well as the entire body. From retinitis pigmentosa to Parkinson’s disease, understanding disease mechanisms has never been more promising.

12/10/2024

Ready to take your cancer research to new heights?

Dive deeper into how proteomics is advancing cancer research with the SomaScan™ Platform. Our high-plex protein analysis provides broader coverage of up to half the human proteome, driving early biomarker discovery and validation. The SomaScan 11K Assay now supports cell lysate and tissue homogenate samples, offering deeper insights into cancer pathways.

Discover more about the applications in translational science and pre-clinical cancer research. https://somalogic.com/cancer/

The SomaScan® Assay measures 7,000 proteins in a 55-μL blood sample and efficiently detectslow-abundance proteins in complex biological samples

11/28/2024

We’re excited to be Gold Sponsors at Precision Medicine and the Future of Genomics 2024 Summit in Doha, Qatar! Visit us at booth 10 in the exhibition hall to connect with our team.

Don’t miss our Scientific Engagement Activity on Tuesday, 3 December at 1:30 pm. Let’s collaborate to shape the future of precision medicine. See you there!

10/28/2024

Lower coefficients of variation mean greater confidence in a platform’s reproducibility - and greater confidence in your data.

Download our poster on optimizing biomarker discovery with a focus on low coefficient of variation in large-scale proteomics:

Median CVs range from ~4.5% to 18.0% for immunoassay technology, up to >30% for mass spectrometry, ~5% for the SomaScan® Assay, and ~10% for the Olink Explore Assay. Large CVs can cause technical variability to overwhelm biological signal.

10/17/2024

Planning to be in Salt Lake City for the American Association of Pharmaceutical Scientists (AAPS) Conference? You are invited to attend the Special Poster Collection on Monday, October 21, from 1:30 pm-2:25 pm!

Hear about the utilization of proteomic surrogates for early detection of unexpected drug benefits at Poster M0930-10-54 with Jessica Chadwick, PhD.

And learn how the SomaScan® Platform provides the largest number of protein measurements and the greatest number of orthogonally confirmed protein reagents in the proteomics industry —11,000 protein measurements simultaneously from sample volumes as low as 55 µl—giving researchers access to half of the human proteome in just one assay – at Booth 1402.

AAPSPharmSci360

10/09/2024

🎉Congratulations to the new Nobel Prize winners in Chemistry, David Baker, Demis Hassabis and John M. Jumper, for their research in protein structures!

We're excited that proteins are now taking center stage in research with these important projects. For more than 20 years we've put our efforts into studying proteins and the potential they have for helping us understand our own biology.

We look forward to seeing, and participating in, what the future of protein research brings!

The Nobel Prize in Chemistry 2024 was divided, one half awarded to David Baker "for computational protein design", the other half jointly to Demis Hassabis and John M. Jumper "for protein structure prediction"

10/07/2024

Expanding the SomaScan® Platform to include more sample types, including CSF, cell lysates and tissue homogenates opens new avenues for biomarker discovery.

The use of high-throughput proteomics in cerebrospinal fluid for neurodegenerative disease research is key to providing information on biological changes occurring in the brain. The SomaScan Platform’s sensitivity to these changes is expected to give researchers a wealth of neurological data.

Learn more about how we’re setting a new standard for discovery: https://www.somalogic.com/somascan-unique-scale

09/20/2024

Join us at in Basel, Switzerland!

Don’t miss our scientific session on Monday, 30 September from 11:05 - 11:30 AM in Conference Room 1.

Visit us at Booth 32 to learn how the SomaScan® Platform can accelerate your research and biomarker discoveries.

09/18/2024

1 week left to register!

Join us for two exclusive symposia focused on Advancing Translational Research through Targeted Proteomics:
📍 Riyadh, Saudi Arabia: Wednesday, 25th September
📍 Dubai, United Arab Emirates: Thursday, 26th September

Don't miss this unique opportunity to dive deep into the world of targeted proteomics with industry experts:
✧ Stephen A. Williams, PhD (Chief Medical Officer, SomaLogic/Standard BioTools)
✧ Tala Khosroheidari, PhD (Senior Director of Global Scientific Engagement at SomaLogic/Standard Biotools)
✧ Anders Elleby (Channel Partner Manager at Standard BioTools)

Registration is FREE but spots are limited! Secure your place now!

Riyadh - https://lnkd.in/gPG5dr36...
Dubai - https://lnkd.in/guNgjXyJ...
hashtag hashtag hashtag hashtag hashtag hashtag hashtag